Strength of Folfirinox data spells the end for Targovax program

Data presented on the Folfirinox chemotherapy regimen at the American Society of Clinical Oncology (ASCO) has spelt the end for Targovax’s (TRVX: NO) TG01, a neoantigen cancer vaccine for resected pancreatic cancer.

The Norwegian company accepts that the vaccine cannot compete with the four-drug modified Folfirinox regimen, after it improved overall survival by 19 months over gemcitabine, according to the data.

Targovax has therefore decided to prioritize and strengthen its development focus on the ONCOS program, which uses genetically-armed oncolytic adenoviruses. ONCOS-102 will be developed in mesothelioma as launch indication, as well as checkpoint inhibitor combinations in cold tumors.